Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Targeted therapy in consolidation setting for lung cancer

Howard West, MD, City Of Hope Comprehensive Cancer Center, Duarte, CA, discusses the implementation of targeted therapy in consolidation setting for unresectable stage III non-small cell lung cancer (NSCLC). Previously, the Phase III SWOG0023 study was the first trial to investigate maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III NSCLC prospectively, which demonstrated a significant difference in overall-survival (OS) favoring placebo. However, SWOG0023 included an unselected population. The ongoing Phase III LAURA (NCT03521154) study is currently exploring the efficacy of maintenance osimertinib in stage III EGFR-mutant NSCLC, and is expected to demonstrate positive results for progression-free survival (PFS). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.